
Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target
Oric Pharmaceuticals (ORIC) Analyst Ratings
Bulls say
ORIC Pharmaceuticals is attractive fundamentally because its pipeline offers two differentiated shots on goal: rinzimetostat in mCRPC and enozertinib in atypical EGFR NSCLC, both supported by encouraging early efficacy and manageable safety signals. The ESMO updates de-risked the story, with enozertinib showing 84% confirmed ORR and 67% intracranial ORR in a high-CNS-burden group, while rinzimetostat plus darolutamide produced a 47% PSA50 rate and encouraging rPFS trends, making the upcoming MEVPRO-1 readout a key validation event. Financially, the company’s modeled opportunity is sizable, including $1.4B peak worldwide sales for rinzimetostat in post-abiraterone mCRPC and cash runway into 2H28, which supports a positive long-term outlook despite clinical-stage risk.
Bears say
ORIC Pharmaceuticals is facing a weakening fundamental case as increasing competition in mCRPC raises the efficacy bar and makes rinzimetostat’s eventual differentiation less certain, especially while Pfizer’s MEVPRO-1 readout in 4Q26 remains the more relevant randomized test. JNJ-6143’s 77% confirmed PSA50 rate, 75% ORR, and 11.0-month median duration of response show that credible alternatives are emerging, while ORIC’s own program is still tied to earlier-stage validation in the Ph 3 Himalayas-1 study. At the same time, safety concerns persist, with Grade ≥3 treatment-related adverse events rising from 10% to 17%, one treatment-related Grade 5 acute kidney injury reported, and metabolic/hepatic toxicity signals that could complicate development and commercialization.
This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Oric Pharmaceuticals (ORIC) Analyst Forecast & Price Prediction
Start investing in Oric Pharmaceuticals (ORIC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Oric Pharmaceuticals (ORIC) Forecast
Oric Pharmaceuticals (ORIC) Analyst Forecast & Price Prediction
Start investing in Oric Pharmaceuticals (ORIC)
Order type
Buy in
Order amount
Est. shares
0 shares